Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Angewandte Chemie (International Ed. in English)
|
March 10, 2001
Functionalized Polymers-Emerging Versatile Tools for Solution-Phase Chemistry and Automated Parallel Synthesis
Andreas Kirschning, Holger Monenschein, Rüdiger Wittenberg
Bioorganic & Medicinal Chemistry Letters
|
May 11, 2012
Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease
Holger Monenschein, Daniel B Horne, Michael D Bartberger, et al.
Journal of the American Chemical Society
|
December 11, 2003
Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation
K C Nicolaou, Yiwei Li, Kazuyuki Sugita, et al.
Journal of the American Chemical Society
|
December 11, 2003
Total synthesis of apoptolidin: construction of enantiomerically pure fragments
K C Nicolaou, Konstantina C Fylaktakidou, Holger Monenschein, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 18, 2013
Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity
Lewis D Pennington, Douglas A Whittington, Michael D Bartberger, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2010
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics
Qingping Zeng, Matthew P Bourbeau, G Erich Wohlhieter, et al.
Journal of Medicinal Chemistry
|
March 7, 2014
Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists
Daniel B Horne, Nuria A Tamayo, Michael D Bartberger, et al.
Journal of Medicinal Chemistry
|
April 16, 2021
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Huikai Sun, Holger Monenschein, Hans H Schiffer, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
Holly A Reichard, Hans H Schiffer, Holger Monenschein, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 2, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Nicola L Brice, Hans H Schiffer, Holger Monenschein, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Angewandte Chemie (International Ed. in English)
|
March 10, 2001
Functionalized Polymers-Emerging Versatile Tools for Solution-Phase Chemistry and Automated Parallel Synthesis
Andreas Kirschning, Holger Monenschein, Rüdiger Wittenberg
Bioorganic & Medicinal Chemistry Letters
|
May 11, 2012
Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease
Holger Monenschein, Daniel B Horne, Michael D Bartberger, et al.
Journal of the American Chemical Society
|
December 11, 2003
Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation
K C Nicolaou, Yiwei Li, Kazuyuki Sugita, et al.
Journal of the American Chemical Society
|
December 11, 2003
Total synthesis of apoptolidin: construction of enantiomerically pure fragments
K C Nicolaou, Konstantina C Fylaktakidou, Holger Monenschein, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 18, 2013
Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity
Lewis D Pennington, Douglas A Whittington, Michael D Bartberger, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2010
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics
Qingping Zeng, Matthew P Bourbeau, G Erich Wohlhieter, et al.
Journal of Medicinal Chemistry
|
March 7, 2014
Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists
Daniel B Horne, Nuria A Tamayo, Michael D Bartberger, et al.
Journal of Medicinal Chemistry
|
April 16, 2021
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Huikai Sun, Holger Monenschein, Hans H Schiffer, et al.
Journal of Medicinal Chemistry
|
July 14, 2021
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
Holly A Reichard, Hans H Schiffer, Holger Monenschein, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 2, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
Nicola L Brice, Hans H Schiffer, Holger Monenschein, et al.
Page
of 2